摘要
探讨甲状腺球蛋白(Tg)和131I全身显像(131I-WBS)在甲状腺乳头癌(PTC)复发监测中的意义。30例PTC患者术后6周,行131I(3.7GBq)首次清除残留甲状腺组织治疗,6个月后再给予131I治疗1次,治疗中同时测定Tg和进行131I-WBS。结果表明,在首次清除残留甲状腺组织治疗时,显像发现淋巴、肺及骨转移6例,其余转移灶于6个月治疗时发现,有3例患者(10%)Tg测定在正常范围,而131I-WBS出现转移灶,4例患者(13.3%)Tg测定异常,而131I-WBS正常。Tg测定和131I-WBS可作为诊断PTC有无转移的重要指标,二者监测复发应联合应用,可互相补充。
To investigate the value of thyroglobulin （Tg） and 131^I-whole body scan （131^I-WBS） on the papillary thyroid carcinoma （PTC） with 131^I therapy after surgical treatment, 30 patients with PTC after surgical treatment were treated with 131^I therapy, and treated again after 6 months. The serum Tg levels in patients were measured, and all patients were also performed 131^I-WBS. The results showed that 6 patients have been found metastases to lymph, lung and bone in first 131^Itherapy. The serum Tg levels in 3 patients were normal, but the 131^I-WBS results were positive. The serum Tg levels in 13. 3% patients were abnormal, but 131^I-WBS was negative. The combined measurement of serum Tg level and 131^I-WBS could be regarded as important index in the diagnosis of metastases of cancer on the patients with papillary thyroid carcinoma.
出处
《标记免疫分析与临床》
CAS
2007年第3期154-155,共2页
Labeled Immunoassays and Clinical Medicine
